ASCO 2021: Adjuvant Nivolumab Following Trimodality Therapy Improves Outcomes and Maintains Quality of Life in Esophageal Cancer
Findings were the result of an expanded analysis of CheckMate 577
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.